

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
56029-9879

In Re Application:

Milbrandt et al.

Serial No.	Filing Date	Examiner	Group Art Unit
09/473,551	12/28/1999	Olga N. Chernyshev	56029-9879



**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \$180.00 is attached.

The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 20-0823 as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of

Credit any overpayment.

Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. ) on

(Date)

Signature

*Kimberly H. Lu*  
Signature  
Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

*Kimberly H. Lu*  
Signature  
Kimberly H. Lu, Reg. No. 51,973  
Thompson Coburn LLP  
One US Bank Plaza  
St. Louis, Missouri 63101-9928  
314-552-6307  
314-552-6307 FAX

Customer No: 021888

**Certificate of Mailing by Express Mail**

I certify that this document and fee is being deposited on October 17, 2002 with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Express Mail No.: EL474185339US

*Kimberly H. Lu*  
Signature of Person Mailing Correspondence

Kimberly H. Lu

Typed or Printed Name of Person Mailing Certificate

Dated: October 17, 2002

*JAN 28 2003*  
RECEIVED  
TECH CENTER 1600/2900

*DEC 05 2002*  
RECEIVED  
TECH CENTER 1600/2900

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))		Docket No. 56029-9879
<p>In Re Application Of: Milbrandt et al.</p> <p>Serial No. 09/473,551 Filing Date 12/28/1999 Examiner Olga N. Chernyshev Group Art Unit 1646</p> <p>Title: GFR (alpha)1-RET SPECIFIC AGONISTS AND METHODS THEREFOR</p>		
<p>Address to: Assistant Commissioner for Patents Washington, D.C. 20231</p> <p>TECH CENTER 1600/2900</p> <p>RECEIVED OCT 22 2002</p>		
<p><b>37 CFR 1.97(b)</b></p> <p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p>		
<p><b>37 CFR 1.97(c)</b></p> <p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p>OR</p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> <p>RECEIVED DEC 05 2002</p> <p>RECEIVED JAN 28 2003</p> <p>TECH CENTER 1600/2900</p>		
<p>10/21/2002 BABRAHA1 00000070 09473551 01 FC:1806 180.00 0P</p>		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p> <p>Sheet <b>1</b> of <b>1</b></p>				<b>Complete if Known</b>	
				Application Number	09/473,551
				Filing Date	12/28/1999
				First Named Inventor	Milbrandt et al.
				Group Art Unit	1646
				Examiner Name	Olga N. Chernyshev
				Attorney Docket Number	56029-9879

<b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	AA	GASH et al., Letters To Nature, Functional Recovery In Parkinsonian Monkeys Treated With GDNF, Vol. 380, pgs. 252-255, 03/21/1996			
	AB	LIN et al., Science, GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons, Vol. 260, pgs. 1130-1132, May 21, 1993			
	AC	TRUPP et al., The Journal of Cell Biology, Peripheral Expression and Biological Activities of GDNF, a New Neurotrophic Factor for Avian and Mammalian Peripheral Neurons, Vol. 130 No. 1, pgs. 137-148, July 1995			
	AD	KOTZBAUER et al., Letters To Nature, Neurturin, A Relative Of Glial-Cell-Line-Derived Neurotrophic Factor, Vol. 384, December 5, 1996			
	AE	TOMAC, et al., PNAS, Effects of Cerebral Ischemia In Mice Deficient in Persephin, Vol. 99, No. 14, pgs. 9521-9526, July 9, 2002			
	AF	MILBRANDT et al., Neuron; Persephin, A Novel Neurotrophic Factor Related to GDNF and Neurturin, Vol. 20, pgs. 245-253, February 1998			
	AG	COHEN, Proc. N.A. S.; Purification of a Nerve-Growth Promoting Protein From the Mouse Salivary Gland and Its Neuro-Cytotoxic Antiserum, pgs. 302-311			
	AH	LEVI-MONTALCINI, Effects of Mouse Tumor Transplantation On The Nervous System, pgs. 330-344			
		<b>RECEIVED</b>			
		DEC 05 2002			
		TECH CENTER 1600/2900			

Examiner Signature		Date Considered
--------------------	--	-----------------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation and signature number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.